Investor Presentaiton

Enhancing BMS leadership by the end of the decade Strong track record 9 new products delivered since 2019 3 first-in-class medicines in 2022 20+ new indications & 45+ approvals across U.S., EU & Japan since 2020 High quality pipeline Registrational pipeline increasing to 12 new assets over the next 18 months Targeting high unmet need with growing commercial potential .. Improved productivity • Deliver -10 INDS per year Increase to -20% PoS from FIH to approval • Achieve median of -6.5 years from FIH to approval Continual generation of new first-in-class or best-in-class medicines Ill Bristol Myers Squibb™ Not for Product Promotional Use 143

View entire presentation